Skip to content
2000
Volume 23, Issue 8
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Introduction/Objective

Schizophrenia with substance use disorder is a complex clinical condition that may increase treatment resistance. Cannabis use disorder is frequently associated with psychosis and the causal link has still to be defined. Partial D agonists may ensure limbic dopamine release normalization while avoiding reduced frontocortical dopamine release, which would contribute to negative symptoms. We aimed to observe the clinical course of patients with schizophrenia comorbid with cannabis use disorder while being treated with oral or long-acting injectable D partial agonists.

Methods

We observed 96 young adults with schizophrenia/schizoaffective disorder comorbid with cannabis use disorder during 18 months of treatment with aripiprazole long-acting injectable or oral aripiprazole or brexpiprazole. The assessment comprised Clinical Global Impressions-Severity, Positive And Negative Syndrome Scale, Brief Psychiatric Rating Scale, Barratt Impulsiveness Scale, and Visual Analog Scale for Craving.

Results

Included were 17 women and 79 men (mean age = 26.89 ± 4.74 years). The sample responded favorably to treatment as assessed by all clinical scales, save for the impulsiveness scale which showed no significant change. The four treatment samples responded well without differences, but employing a general linear model, long-acting injectable aripiprazole and brexpiprazole were better and similar on all clinical and craving scales compared to oral aripiprazole and to other antipsychotics. Long-acting injectable aripiprazole fared better than brexpiprazole on general psychopathology, negative symptoms, and craving, while the reverse was true for global severity. However, the sample size imbalance did not allow for drawing strong conclusions. We found no significant treatment resistance in our 96-patient sample.

Conclusion

Partial D agonists may treat comorbid schizophrenia/schizoaffective disorder and cannabis use disorder, improving the symptoms of both disorders and substance craving.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X350599241214042724
2025-01-16
2025-10-28

  • From This Site

    /content/journals/cn/10.2174/011570159X350599241214042724
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KaneJ.M. RifkinA. QuitkinF. NayakD. Ramos-LorenziJ. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.Arch. Gen. Psychiatry1982391707310.1001/archpsyc.1982.04290010048009 6275811
     [Google Scholar]
  2. CrowT.J. MacMillanJ.F. JohnsonA.L. JohnstoneE.C. A randomised controlled trial of prophylactic neuroleptic treatment.Br. J. Psychiatry1986148212012710.1192/bjp.148.2.120 2870753
     [Google Scholar]
  3. WeidenP. GlazerW. Assessment and treatment selection for “revolving door” inpatients with schizophrenia.Psychiatr. Q.199768437739210.1023/A:1025499131905 9355136
     [Google Scholar]
  4. KasperS. First-episode schizophrenia: The importance of early intervention and subjective tolerability.J. Clin. Psychiatry199960Suppl. 2359 10625193
     [Google Scholar]
  5. McIntyreR.S. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: The UNITE global survey.J. Clin. Psychiatry200970Suppl. 3051110.4088/JCP.7075su1c.0219570496
     [Google Scholar]
  6. StoneJ.M. RouxS. TaylorD. MorrisonP.D. First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse.Ther. Adv. Psychopharmacol.201881233333610.1177/2045125318795130 30524701
     [Google Scholar]
  7. HuntG.E. LargeM.M. ClearyM. LaiH.M.X. SaundersJ.B. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis.Drug Alcohol Depend.201819123425810.1016/j.drugalcdep.2018.07.011 30153606
     [Google Scholar]
  8. HasanA. FalkaiP. WobrockT. LiebermanJ. GlenthøjB. GattazW.F. ThibautF. MöllerH.J. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation.World J. Biol. Psychiatry201516314217010.3109/15622975.2015.1009163 25822804
     [Google Scholar]
  9. CrockfordD. AddingtonD. Canadian Schizophrenia guidelines: Schizophrenia and other psychotic disorders with coexisting substance use disorders.Can. J. Psychiatry201762962463410.1177/0706743717720196 28886671
     [Google Scholar]
  10. VitaliM. MistrettaM. AlessandriniG. CorialeG. RomeoM. AttiliaF. RotondoC. SorboF. PisciottaF. AttiliaM.L. CeccantiM. Pharmacological treatment for dual diagnosis: A literature update and a proposal of intervention.Riv. Psichiatr.201853316016910.1708/2925.29419 29912219
     [Google Scholar]
  11. PriceS.A. BrahmN.C. Antipsychotic treatment of adolescent dual diagnosis patients.J. Pediatr. Pharmacol. Ther.201116422623610.5863/1551‑6776‑16.4.226 22768007
     [Google Scholar]
  12. KumarA. DattaS.S. WrightS.D. FurtadoV.A. RussellP.S. Atypical antipsychotics for psychosis in adolescents.Cochrane Libr.2013201310CD00958210.1002/14651858.CD009582.pub2 24129841
     [Google Scholar]
  13. RubioG. MartínezI. PonceG. Jiménez-ArrieroM.A. López-MuñozF. ÁlamoC. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity.Can. J. Psychiatry200651853153910.1177/070674370605100808 16933590
     [Google Scholar]
  14. McEvoyJ.P. FreudenreichO. LevinE.D. RoseJ.E. Haloperidol increases smoking in patients with schizophrenia.Psychopharmacology (Berl.)1995119112412610.1007/BF02246063 7675943
     [Google Scholar]
  15. StahlS.M. Stahl’s Essential Psychopharmacology.5th edCambridge, UKCambridge University Press202110.1017/9781108975292
     [Google Scholar]
  16. BurrisK.D. MolskiT.F. XuC. RyanE. TottoriK. KikuchiT. YoccaF.D. MolinoffP.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.J. Pharmacol. Exp. Ther.2002302138138910.1124/jpet.102.033175 12065741
     [Google Scholar]
  17. RivaM.A. Di SciascioG. Aripiprazole: From pharmacological profile to clinical use.Neuropsychiatr. Dis. Treat.2015112635264710.2147/NDT.S88117 26508859
     [Google Scholar]
  18. Swainston HarrisonT. PerryC.M. Aripiprazole.Drugs200464151715173610.2165/00003495‑200464150‑00010 15257633
     [Google Scholar]
  19. MaedaK. SuginoH. AkazawaH. AmadaN. ShimadaJ. FutamuraT. YamashitaH. ItoN. McQuadeR.D. MørkA. PehrsonA.L. HentzerM. NielsenV. BundgaardC. ArntJ. StensbølT.B. KikuchiT. BrexpiprazoleI. In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.J. Pharmacol. Exp. Ther.2014350358960410.1124/jpet.114.213793 24947465
     [Google Scholar]
  20. KishiT. IkutaT. MatsudaY. SakumaK. IwataN. Aripiprazole vs. brexpiprazole for acute schizophrenia: A systematic review and network meta-analysis.Psychopharmacology (Berl.)202023751459147010.1007/s00213‑020‑05472‑5 32002559
     [Google Scholar]
  21. MaedaK. LerdrupL. SuginoH. AkazawaH. AmadaN. McQuadeR.D. StensbølT.B. BundgaardC. ArntJ. KikuchiT. BrexpiprazoleII:. Antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.J. Pharmacol. Exp. Ther.2014350360561410.1124/jpet.114.213819 24947464
     [Google Scholar]
  22. CaraciF. SantagatiM. CarusoG. CannavòD. LeggioG.M. SalomoneS. DragoF. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: Focus on brexpiprazole and pimavanserin.F1000 Res.20209F100010.12688/f1000research.22662.1
     [Google Scholar]
  23. StummerL. MarkovicM. MaroneyM. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer’s disease.Neurodegener. Dis. Manag.202010420521710.2217/nmt‑2020‑0013 32618483
     [Google Scholar]
  24. VaradharajanA. DavisA.D. GhoshA. JagtapT. XavierA. MenonA.J. RoyD. GandhiS. GregorT. Guidelines for pharmacotherapy in Alzheimer’s disease - A primer on FDA-approved drugs.J. Neurosci. Rural Pract.202314456657310.25259/JNRP_356_2023 38059250
     [Google Scholar]
  25. MarinheiroG. DantasJ.M. MutarelliA. Menegaz de AlmeidaA. MonteiroG.A. ZerlottoD.S. TellesJ.P.M. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s disease: A meta-analysis of randomized controlled trials.Neurol. Sci.2024451046794686Epub ahead of print10.1007/s10072‑024‑07576‑8 38763935
     [Google Scholar]
  26. RicciV. SarniA. MartinottiG. MainaG. Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: Efficacy, safety, and cognitive impacts. A narrative review.Int. Clin. Psychopharmacol.202420241410.1097/YIC.0000000000000559 38941160
     [Google Scholar]
  27. DianaM. The dopamine hypothesis of drug addiction and its potential therapeutic value.Front. Psychiatry201126410.3389/fpsyt.2011.00064 22144966
     [Google Scholar]
  28. VergneD. AntonR. Aripiprazole: A drug with a novel mechanism of action and possible efficacy for alcohol dependence.CNS Neurol. Disord. Drug Targets201091505410.2174/187152710790966731 20201815
     [Google Scholar]
  29. RibeiroE.L.A. de Mendonça LimaT. VieiraM.E.B. StorpirtisS. AguiarP.M. Efficacy and safety of aripiprazole for the treatment of schizophrenia: An overview of systematic reviews.Eur. J. Clin. Pharmacol.201874101215123310.1007/s00228‑018‑2498‑1 29905899
     [Google Scholar]
  30. RicciV. De BerardisD. MainaG. Third-generation antipsychotics and lurasidone in the treatment of substance-induced psychoses: A narrative review.Healthcare (Basel)202412333910.3390/healthcare12030339 38338224
     [Google Scholar]
  31. FornaroM. FuscoA. AnastasiaA. CattaneoC.I. De BerardisD. Brexpiprazole for treatment-resistant major depressive disorder.Expert Opin. Pharmacother.201920161925193310.1080/14656566.2019.1654457 31431092
     [Google Scholar]
  32. KoskinenJ. HakkoH. RiipinenP. SihvolaN. HaltA.H. A letter to the editor: The impact of comorbid depression and substance use disorder on drivers with a psychotic disorder killed in motor vehicle accidents. Schizophr. Res. 202427024624810.1016/j.schres.2024.06.037
     [Google Scholar]
  33. TroviniG. AmiciE. BaucoP. MatroneM. LombardozziG. GiovanettiV. KotzalidisG.D. De FilippisS. A comprehensive evaluation of adverse childhood experiences, social–emotional impairments, and neurodevelopmental disorders in cannabis-use disorder: Implications for clinical practice.Eur. Psychiatry2023661e7710.1192/j.eurpsy.2023.2436 37702087
     [Google Scholar]
  34. PosnerK. BrownG.K. StanleyB. BrentD.A. YershovaK.V. OquendoM.A. CurrierG.W. MelvinG.A. GreenhillL. ShenS. MannJ.J. The Columbia-suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults.Am. J. Psychiatry2011168121266127710.1176/appi.ajp.2011.10111704 22193671
     [Google Scholar]
  35. WechslerD.A. Wechsler Adult Intelligence Scale.4th edSan Antonio, TXPsychological Corporation200832810.1037/t15169‑000
     [Google Scholar]
  36. GuyW. ECDEU Assessment Manual for Psychopharmacology, Revised; US Department of Health, Education, and Welfare Publication.Rockville, MDADM197676338
     [Google Scholar]
  37. KayS.R. FiszbeinA. OplerL.A. The positive and negative syndrome scale (PANSS) for schizophrenia.Schizophr. Bull.198713226127610.1093/schbul/13.2.261 3616518
     [Google Scholar]
  38. PancheriP. BrugnoliR. CarilliL. Delle ChiaieR. MarconiP.L. PetrucciR.M. Dimensional assessment of schizophrenic symptomatology. Validation of the Italian version of the Positive And Negative Symptoms Scale (PANSS).Giorn. Ital. Psychopathol.199516075
     [Google Scholar]
  39. VenturaJ. LukoffD. NuechterleinK.H. LibermanR.P. GreenM. ShanerA. Training and quality assurance with the Brief psychiatric rating scale: “The drift busters” appendix 1: Brief Psychiatric Rating Scale (BPRS) expanded version (40) scales, anchor points and administration manual.Int. J. Methods Psychiatr. Res.19933221244
     [Google Scholar]
  40. RonconeR. VenturaJ. ImpallomeniM. FalloonI.R. MorosiniP.L. ChiaravalleE. CasacchiaM. Reliability of an Italian standardized and expanded brief psychiatric rating scale (BPRS 4.0) in raters with high vs. low clinical experience.Acta Psychiatr. Scand.19991003229236
     [Google Scholar]
  41. NicholsonA.N. Visual analogue scales and drug effects.Br. J. Clin. Pharmacol.1978634
     [Google Scholar]
  42. PattonJ.H. StanfordM.S. BarrattE.S. Factor structure of the Barratt impulsiveness scale.J. Clin. Psychol.1995516768774
     [Google Scholar]
  43. FirstM.B. WilliamsJ.B.W. KargR.S. SpitzerR.L. Structured Clinical Interview for DSM-5 Disorders-Clinician Version SCID-5-CV.Washington, DCAmerican Psychiatric Association Publishing, Inc.2016
     [Google Scholar]
  44. ShapiroS.S. WilkM.B. An analysis of variance test for normality (complete samples).Biometrika1965523-459161110.1093/biomet/52.3‑4.591
     [Google Scholar]
  45. BonferroniC.E. Statistical class theory and probability calculus;Publications of the Royal Institute of Economic and Commercial Sciences of Florence: Florence, Italy1936
     [Google Scholar]
  46. WatanabeY. YamadaS. OtsuboT. KikuchiT. Brexpiprazole for the treatment of schizophrenia in adults: An overview of its clinical efficacy and safety and a psychiatrist’s perspective.Drug Des. Devel. Ther.2020145559557410.2147/DDDT.S240859 33376301
     [Google Scholar]
  47. CorrellC.U. SkubanA. OuyangJ. HobartM. PfisterS. McQuadeR.D. NyilasM. CarsonW.H. SanchezR. ErikssonH. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial.Am. J. Psychiatry2015172987088010.1176/appi.ajp.2015.14101275 25882325
     [Google Scholar]
  48. LombardozziG. TroviniG. AmiciE. KotzalidisG.D. PerriniF. GiovanettiV. Di GiovanniA. De FilippisS. Brexpiprazole in patients with schizophrenia with or without substance use disorder: An observational study.Front. Psychiatry202314132123310.3389/fpsyt.2023.1321233 38111619
     [Google Scholar]
  49. CorrellC.U. KimE. SliwaJ.K. HammW. GopalS. MathewsM. VenkatasubramanianR. SakladS.R. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: An overview.CNS Drugs2021351395910.1007/s40263‑020‑00779‑5 33507525
     [Google Scholar]
  50. KarlsgodtK.H. SunD. CannonT.D. Structural and functional brain abnormalities in schizophrenia.Curr. Dir. Psychol. Sci.201019422623110.1177/0963721410377601 25414548
     [Google Scholar]
  51. VitaA. De PeriL. DesteG. SacchettiE. Progressive loss of cortical gray matter in schizophrenia: A meta-analysis and meta-regression of longitudinal MRI studies.Transl. Psychiatry2012211e19010.1038/tp.2012.116 23168990
     [Google Scholar]
  52. VolkowN.D. FowlerJ.S. WangG-J. SwansonJ.M. Dopamine in drug abuse and addiction: Results from imaging studies and treatment implications.Mol. Psychiatry20049655756910.1038/sj.mp.4001507 15098002
     [Google Scholar]
  53. WalshS.L. CunninghamK.A. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine.Psychopharmacology (Berl.)19971301415810.1007/s002130050210 9089847
     [Google Scholar]
  54. SaundersB.T. YagerL.M. RobinsonT.E. Cue-evoked cocaine “craving”: Role of dopamine in the accumbens core.J. Neurosci.20133335139891400010.1523/JNEUROSCI.0450‑13.2013 23986236
     [Google Scholar]
  55. AlonsoI.P. O’ConnorB.M. BryantK.G. MandalaywalaR.K. EspañaR.A. Incubation of cocaine craving coincides with changes in dopamine terminal neurotransmission.Addict. Neurosci.2022310002910.1016/j.addicn.2022.100029 36081573
     [Google Scholar]
  56. WeberS.J. KawaA.B. BeutlerM.M. KuhnH.M. MoutierA.L. WestlakeJ.G. KoyshmanL.M. MorenoC.D. WunschA.M. WolfM.E. Dopamine transmission at D1 and D2 receptors in the nucleus accumbens contributes to the expression of incubation of cocaine craving.NeuropsychopharmacologyEpub ahead of print10.1038/s41386‑024‑01992‑239300272 2024, 2024.
     [Google Scholar]
  57. MoralesA.M. KohnoM. RobertsonC.L. DeanA.C. MandelkernM.A. LondonE.D. Midbrain dopamine D2/D3 receptor availability and drug craving are associated with mesocorticolimbic gray matter volume in methamphetamine users.Mol. Psychiatry201520665810.1038/mp.2015.59 25993553
     [Google Scholar]
  58. MojtabaiR. SusukidaR. FarokhniaM. NguyenT.Q. DunnK.E. Amin-EsmaeiliM. Trajectories of craving in the course of pharmacotherapy trials for methamphetamine use disorder.Addiction2024119101803181210.1111/add.16610 38984671
     [Google Scholar]
  59. BlumK. BadgaiyanR. BravermanE. DushajK. LiM. ThanosP. DemetrovicsZ. FeboM. Hypothesizing that, a pro-dopamine regulator (KB220Z) should optimize, but not hyper-activate the activity of trace amine-associated receptor 1 (TAAR-1) and induce anti-craving of psychostimulants in the long-term.J. Reward Defic. Syndr. Addict. Sci.201621142110.17756/jrdsas.2016‑023 28317038
     [Google Scholar]
  60. MachielsenM. BeduinA.S. DekkerN. KahnR.S. LinszenD.H. van OsJ. WiersmaD. BruggemanR. CahnW. de HaanL. KrabbendamL. Myin-GermeysI. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.J. Psychopharmacol.201226118919510.1177/0269881111408957 21768161
     [Google Scholar]
  61. FilbeyF.M. DeWittS.J. Cannabis cue-elicited craving and the reward neurocircuitry.Prog. Neuropsychopharmacol. Biol. Psychiatry2012381303510.1016/j.pnpbp.2011.11.001 22100353
     [Google Scholar]
  62. ChukwuekeC.C. KowalczykW.J. Di CianoP. GendyM. TaylorR. HeishmanS.J. Le FollB. Exploring the role of the Ser9Gly (rs6280) Dopamine D3 receptor polymorphism in nicotine reinforcement and cue-elicited craving.Sci. Rep.2020101408510.1038/s41598‑020‑60940‑4 32139730
     [Google Scholar]
  63. RoddZ.A. AnstromK.K. KnappD.J. RaczI. ZimmerA. SerraS. BellR.L. WoodwardD.J. BreeseG.R. ColomboG. Factors mediating alcohol craving and relapse: Stress, compulsivity, and genetics.Alcohol. Clin. Exp. Res.20052971325133310.1097/01.ALC.0000171487.62079.A3 16088996
     [Google Scholar]
  64. BlumK. LiuY. ShrinerR. GoldM.S. Reward circuitry dopaminergic activation regulates food and drug craving behavior.Curr. Pharm. Des.201117121158116710.2174/138161211795656819 21492092
     [Google Scholar]
  65. Haddad-TóvolliR. RamírezS. Muñoz-MorenoE. Milà-GuaschM. Miquel-RioL. PozoM. ChiviteI. AltirribaJ. ObriA. Gómez-ValadésA.G. ToledoM. EyreE. BortolozziA. ValjentE. SoriaG. ClaretM. Food craving-like episodes during pregnancy are mediated by accumbal dopaminergic circuits.Nat. Metab.20224442443410.1038/s42255‑022‑00557‑1 35379970
     [Google Scholar]
  66. CuomoI. KotzalidisG.D. de PersisS. PiacentinoD. PerriniF. AmiciE. De FilippisS. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: Impact on clinical status, substance craving, and quality of life.Neuropsychiatr. Dis. Treat.2018141645165610.2147/NDT.S171002 29950846
     [Google Scholar]
  67. MartinottiG. OrsoliniL. FornaroM. VecchiottiR. De BerardisD. IasevoliF. TorrensM. Di GiannantonioM. Aripiprazole for relapse prevention and craving in alcohol use disorder: Current evidence and future perspectives.Expert Opin. Investig. Drugs201625671972810.1080/13543784.2016.1175431 27098451
     [Google Scholar]
  68. ErdoganA. KulaksizogluB. BingolM.S. CinemreB. KulogluM.M. Successful treatment with long-acting injectable aripiprazole monohydrate for two patients with dual diagnosis - Substance use disorder and psychotic disorder.Dusunen Adam20213410210610.14744/DAJPNS.2021.00126
     [Google Scholar]
  69. SzermanN. Basurte-VillamorI. VegaP. Martinez-RagaJ. Parro-TorresC. Cambra AlmergeJ. Grau-LópezL. De MatteisM. AriasF. Once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring substance use disorders: A multicentre, observational study.Drugs Real World Outcomes202071758310.1007/s40801‑020‑00178‑8 32026379
     [Google Scholar]
  70. ÖzbekS.U. AlptekinK. Thought disorder as a neglected dimension in schizophrenia.Alpha Psychiatry202123151110.5152/alphapsychiatry.2021.21371 36425242
     [Google Scholar]
  71. KirschbaumK.M. MüllerM.J. MalevaniJ. MobascherA. BurchardtC. PielM. HiemkeC. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.World J. Biol. Psychiatry20089321221810.1080/15622970701361255 17853280
     [Google Scholar]
  72. HartX.M. HiemkeC. EichentopfL. LenseX.M. ClementH.W. ConcaA. FaltracoF. FlorioV. GrünerJ. Havemann-ReineckeU. MoldenE. PaulzenM. SchoretsanitisG. RiemerT.G. GründerG. Therapeutic reference range for aripiprazole in schizophrenia revised: A systematic review and metaanalysis.Psychopharmacology (Berl.)2022239113377339110.1007/s00213‑022‑06233‑2 36195732
     [Google Scholar]
/content/journals/cn/10.2174/011570159X350599241214042724
Loading
Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder
Curr. Neuropharmacol. 23, 996 (2025); https://doi.org/10.2174/011570159X350599241214042724
/content/journals/cn/10.2174/011570159X350599241214042724
/content/journals/cn/10.2174/011570159X350599241214042724
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): aripiprazole; cannabis use disorder; comorbidity; long-acting injectable; oral; Partial dopamine agonist antipsychotic drugs; schizoaffective disorder; schizophrenia; substance use disorders

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test